Clinical Trial Update: CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CPI-613 (devimistat) in combination with metformin for relapsed or refractory acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Granulocytic Sarcoma

Drugs mentioned

• CPI-613 (devimistat)
• metformin (metformin)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Status: WITHDRAWN